Arrowhead Secures Maiden Approval, First FDA Nod for Rare Genetic Metabolic Disorder

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta caused its own stock to drop during the gene therapy maker’s safety troubles this summer.